Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020

被引：4

作者：

Ryder, Robert E. J. ^{[1
]}

Abdul-Ghani, Muhammad A. ^{[2
]}

Defronzo, Ralph A. ^{[2
]}

机构：

[1] City Hosp, Birmingham, W Midlands, England

[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

来源：

BRITISH JOURNAL OF DIABETES | 2020年 / 20卷 / 02期

关键词：

Type; 2; diabetes; cardiovascular outcome studies; pioglitazone; SGLT2; inhibitors; GLP-1 receptor agonist; heart failure; stroke; SGLT2; INHIBITORS; LIRAGLUTIDE COMPLEMENT; COULD METFORMIN; HEART-FAILURE; PIOGLITAZONE; EMPAGLIFLOZIN; GLIMEPIRIDE; WAKE;

D O I：

10.15277/bjd.2020.276

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：84 / 88

页数：5